BioArctics New Antibodies Targeting Alzheimers Disease Receives Japanese Patent

BioArctics New Antibodies Targeting Alzheimers Disease Receives Japanese Patent

By, Admin 13 May 2021

BioArctic announced that the Japanese Patent Office (JPO) has allowed the company's Japanese patent application 2017-083057 for novel antibodies that could be developed into a treatment for Alzheimer's disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aß) and are linked to the company's project AD1503. BioArctic received a patent in Europe based on the same antibodies in January 2021.The allowed patent application focuses on novel antibodies which target pE3-Aß, a specific truncated form of amyloid beta. Monomers of pE3-Aß are highly prone to aggregate, leading to the formation of harmful soluble Aß aggregates (protofibrils) which could cause debilitating cognitive and other symptoms in Alzheimer's disease.“The patent underlines BioArctic's commitment in the brain diseases field in general and in Alzheimer's disease specifically. With more than 50 million people globally living with dementia there is a large medical need. We continue to work diligently to develop and give these patients access to treatments that affect the underlying disease,” said Gunilla Osswald, CEO, BioArctic

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!